Analysis Of Income And Expense [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
2,087,000 EUR
900,000 EUR
Material income and expense [abstract]
Research and development expense
14,421,000 EUR
10,272,000 EUR
Miscellaneous other operating income
2,127,000 EUR
1,487,000 EUR
Miscellaneous other operating expense
- EUR
12,000 EUR
Selling, general and administrative expense [abstract]
General and administrative expense
5,546,000 EUR
3,517,000 EUR
Revenue and other operating income
4,214,000 EUR
2,387,000 EUR
Operating expense
20,207,000 EUR
14,024,000 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates and joint ventures accounted for using equity method
147,000 EUR
130,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
15,380,000 EUR
15,380,000 EUR
10,770,000 EUR
10,770,000 EUR
11,906,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.